New Two-Pronged attack on breast cancer aims to spare hearts
NCT ID NCT07372079
Summary
This study is testing a new two-in-one immunotherapy drug called QL1706, given with chemotherapy before surgery for early triple-negative breast cancer. The goal is to shrink tumors and see if some patients can safely skip a type of chemotherapy that can harm the heart long-term. About 40 patients will receive the treatment, and their response will guide whether they need the full chemotherapy course or can go straight to surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.